News
ROIV
10.88
-0.18%
-0.02
Roivant Sciences: Cashing In On Vants And Ventures
Roivant Sciences sold a subsidiary for $7.1 billion and plans a $1.5 billion stock buyback. The company is well-capitalized with $6.67 billion in cash against minimal liabilities. Its pipeline includes promising drugs like IMVT-1402. Roivant is down nearly 5% since my last update on the company.
Seeking Alpha · 1d ago
Critical Insights From Roivant Sciences Analyst Ratings: What You Need To Know
7 analysts have expressed a variety of opinions on Roivant Sciences (NASDAQ:ROIV) over the past quarter. The company has an average price target of $18.0. The average 12-month price target is higher than the previous average of $16.25. The biopharmaceutical company is a leader in the health care sector.
Benzinga · 3d ago
Weekly Report: what happened at ROIV last week (0415-0419)?
Weekly Report · 3d ago
Roivant Sciences Price Target Maintained With a $18.00/Share by HC Wainwright & Co.
Dow Jones · 3d ago
HC Wainwright & Co. Reiterates Buy on Roivant Sciences, Maintains $18 Price Target
Benzinga · 3d ago
Analysts Are Bullish on Top Healthcare Stocks: Reviva Pharmaceuticals Holdings (RVPH), Roivant Sciences (ROIV)
TipRanks · 3d ago
Roivant Sciences Currently Down Eight Consecutive Days, on Pace for Longest Losing Streak Since August 2022 -- Data Talk
Roivant Sciences Ltd. Is currently at $10.58, down $0.13 or 1.17%. Would be lowest close since April 1, 2024. Currently down eight consecutive days; down 9.84% over this period. Down 21.71% from its all-time closing high of $13.52.
Dow Jones · 04/17 18:49
Weekly Report: what happened at ROIV last week (0408-0412)?
Weekly Report · 04/15 12:15
Arbutus Biopharma: The Markman Win Is A Good Milestone But Uncertainty Remains
Arbutus Biopharma and Roivant won a crucial claims construction ruling in their patent infringement lawsuit against Moderna. The ruling opens the way for a potential win against the pharma giant, but uncertainties remain regarding the lawsuit and Arbutus' pipeline. The potential litigation payout could be significant, but the company's expensive pipeline development and cash burn rate are concerns.
Seeking Alpha · 04/10 08:22
Weekly Report: what happened at ROIV last week (0401-0405)?
Weekly Report · 04/08 12:21
Analysts Anticipate FXH Will Reach $123
NASDAQ · 04/08 10:38
UPDATE 1-Moderna shares fall after judge sides with Arbutus in patent fight
Moderna shares fall after judge sides with Arbutus in patent fight. Shares of Moderna MRNA.O fell 4% in afternoon trading. A U.S. Judge interpreted parts of the patents in ways that strengthened Ar butus' case. The lawsuit is related to Moderna's blockbuster COVID-19 vaccines.
Reuters · 04/03 18:48
BUZZ-Moderna slides after judge sides with Arbutus in patent fight
U.S. Judge sides with Arbutus in patent infringement lawsuit related to MRNA's blockbuster vaccines. Shares of Moderna slide 3.5% to $100 after the news. MRNA is a joint venture of MRNA and Roivant Sciences. Ar butus shares up 12.1% in after-hours trading.
Reuters · 04/03 18:15
Arbutus Biopharma jumps after patent victory in fight with Moderna
Seeking Alpha · 04/03 16:27
Roivant Sciences Price Target Raised to $18.00/Share From $16.00 by Goldman Sachs
Dow Jones · 04/03 15:28
Roivant Sciences Is Maintained at Buy by Goldman Sachs
Dow Jones · 04/03 15:28
Goldman Sachs Maintains Buy on Roivant Sciences, Raises Price Target to $18
Benzinga · 04/03 15:18
Analysts Offer Insights on Healthcare Companies: Roivant Sciences (ROIV), Terns Pharmaceuticals (TERN) and Altimmune (ALT)
3 analysts have maintained Buy ratings on Roivant Sciences, Terns Pharmaceuticals and Altimmune. The Healthcare sector is a hot area for insiders to make moves following their insider activities. The analysts maintain bullish sentiments on all 3 stocks in a report released today. Roivant sciences, terns pharmaceuticals and altimmune are all in the healthcare sector.
TipRanks · 04/03 12:11
Roivant Sciences Price Target Raised to $18.00/Share From $17.00 by HC Wainwright & Co.
Dow Jones · 04/03 11:15
Roivant Sciences Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 04/03 11:15
More
Webull provides a variety of real-time ROIV stock news. You can receive the latest news about Roivant Sciences through multiple platforms. This information may help you make smarter investment decisions.
About ROIV
Roivant Sciences Ltd. is a commercial-stage biopharmaceutical company that seeks to improve the lives of patients by accelerating the development and commercialization of medicines that matter. The Company’s pipeline is focused on inflammation and immunology and includes VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; batoclimab and IMVT-1402, fully human monoclonal antibodies targeting the neonatal Fc receptor (FcRn) in development across several IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody in development for ulcerative colitis and Crohn’s disease, in addition to various other therapies in various stages of clinical development. The Company advances its pipeline by creating nimble subsidiaries or Vants to develop and commercialize its medicines and technologies. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business.